Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.49 |
| ▸ | TACR1 | P25103 | 3/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105975 | 1.00 | GPR119 (0.49) | GPR119TACR1PDE4BLMNADPP4 | |
| SCHEMBL4711321 | 0.92 | TACR1 (0.51) | GPR119TACR1PDE4BLMNADPP4 | |
| SCHEMBL4756256 | 0.90 | GPR119 (0.50) | GPR119TACR1PDE4BPDE4APDE4C | |
| SCHEMBL12652817 | 0.89 | PDE4B (0.45) | GPR119TACR1PDE4BPDE4APDE4C | |
| SCHEMBL12618333 | 0.89 | PDE4B (0.45) | GPR119TACR1PDE4BPDE4APDE4C | |
| SCHEMBL14920223 | 0.88 | PDE4B (0.44) | GPR119TACR1PDE4BDPP4PDE4A | |
| SCHEMBL14934600 | 0.88 | PDE4B (0.44) | GPR119TACR1PDE4BDPP4PDE4A | |
| SCHEMBL18780282 | 0.88 | PDE4B (0.44) | GPR119TACR1PDE4BDPP4PDE4A | |
| SCHEMBL14921678 | 0.88 | PDE4B (0.44) | GPR119TACR1PDE4BDPP4PDE4A | |
| SCHEMBL14921758 | 0.88 | PDE4B (0.44) | GPR119TACR1PDE4BDPP4PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153658-B2 | Piperidine derivative or salt thereof | ASTELLAS PHARMA, INC. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029687-A1 | PIPERIDINE DERIVATIVE OR SALT THEREOF | CASR, CYP2R1, HCAR1 | GPR119 78/4885TACR1 99/4885PDE4B 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.